Two New Analyses Show Cost Effectiveness of rifaximin-α 550mg Treatment in Belgian and Dutch Patients With Recurrent Hepatic Encephalopathy

News provided by

Norgine B.V.

19 Nov, 2015, 07:00 GMT

LONDON, November 19, 2015 /PRNewswire/ --

  • The average cost of care in Belgian patients using real world evidence was shown to be €31,262 for rifaximin-α 550mg plus lactulose versus €44,190 for lactulose alone [1]
  • In a Dutch societal framework rifaximin-α 550mg has demonstrated an incremental cost-effectiveness ratio of €31,897 [2]

Norgine B.V. has presented new analyses demonstrating the cost effectiveness of XIFAXAN® / TARGAXAN® 550 (rifaximin-α 550mg) treatment in Belgian and Dutch cirrhotic patients with recurrent hepatic encephalopathy with standard of care (lactulose) versus standard of care alone.[1],[2] These data were presented at the ISPOR Annual Congress 2015, Milan, Italy.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )

The Belgian analyses demonstrate that over a five-year time horizon, treatment with rifaximin-α 550mg plus lactulose was both less costly and more effective than with lactulose alone. The analysis was derived from estimates of cost and quality adjusted life year (QALY) measures, which were based on key parameters, including length of hospital stay and number of hospital admissions.

In Dutch patients, the data show use of rifaximin-α 550mg plus lactulose represented good use of economic resource and was cost-effective compared with lactulose alone. Outcome metrics were incremental cost effectiveness ratios (ICERs) derived from QALY estimates and estimates of impact of work productivity loss upon patient/carer using a friction cost method reflecting patient and societal considerations in the model.

Both studies showed positive data for rifaximin-α 550mg, demonstrating a cost saving in Belgium of €12,927 per person over a 5 year time horizon. In the Netherlands, a cost effective base-case ICER of €31,897 over a lifetime horizon was demonstrated.[1],[2]

Peter Martin, Chief Operating Officer at Norgine said "These new analyses are significant because they further demonstrate the value of XIFAXAN® / TARGAXAN® 550 as an effective treatment to manage hepatic encephalopathy, a debilitating condition that currently has no cure apart from liver transplantation."

See full release on http://www.norgine.com

References 

1. Evaluation of the cost effectiveness of rifaximin-α 550mg in the reduction of recurrence of overt hepatic encephalopathy in Belgium. ISPOR Annual Congress 2015, Abstract PGI25.

2. Evaluation of the cost effectiveness and societal impact of rifaximin-α 550mg in the reduction of recurrence of overt hepatic encephalopathy in the Netherlands. ISPOR Annual Congress 2015, Abstract PGI38.

Media Contacts:
Isabelle Jouin, T: +44-(0)1895-453643
Charlotte Andrews, T: +44-(0)1895-453607
Follow us @norgine